Secondary prevention and treatment innovation of early stage Non-Small Cell Lung Cancer: impact on diagnostic-therapeutic pathway from a multidisciplinary perspective

Lung cancer (LC) is the second incident solid tumor and the first cause of cancer-related death worldwide, with more than two million new cases and about 1.800.000 deaths in 2020[1]. In Italy, more than 41.000 new cases have been estimated in 2020 with about 34.000 cancer-related deaths estimated in 2021[2]. Five-year survival rate of LC patients is 15% to 22%, strictly correlated with histological subtype and stage at the diagnosis[1]. Although the detrimental effect of tobacco smoking on incidence and mortality of LC is well established, in Italy smokers amount to more than 14 million people (24.5% of the overall Italian population), with higher incidence in young males and females (25 to 49 years old)[3].

Source: Cancer Treatment Reviews - March 16, 2023 Category: Cancer & Oncology Authors: Giulia Pasello, Daniela Scattolin, Laura Bonanno, Francesca Caumo, Andrea Dell'Amore, Elena Scagliori, Mariaenrica Tin è, Fiorella Calabrese, Gaetano Benati, Matteo Sepulcri, Cristina Baiocchi, Michele Milella, Federico Rea, Valentina Guarneri Tags: Hot Topic Source Type: research